Artivion, Inc. (AORT)

NYQ – Real Time Price. Currency in USD

23.61

+0.95 (4.19%)

At close: Jun 26, 2026, 4:00 PM EDT

23.62

+0.01 (0.04%)

After-hours: Jun 26, 2026, 6:16 PM EDT

10.06.2026

Artivion to Participate in the 2026 Truist Securities MedTech Conference

ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor Hotel. The Company's fireside chat is scheduled to begin at 1:00 p.m.

18.05.2026

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for.

18.05.2026

Artivion Completes Acquisition of Endospan Ltd.

ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System.

11.05.2026

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may have made regarding its financial statements, business operations and prospects.

10.05.2026

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

09.05.2026

Artivion Q1 Earnings Call Highlights

Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.

08.05.2026

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.

Videos

No Data

There is no data to display

Press releases

10.06.2026

Artivion to Participate in the 2026 Truist Securities MedTech Conference

18.05.2026

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

18.05.2026

Artivion Completes Acquisition of Endospan Ltd.

11.05.2026

Artivion, Inc. (AORT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Artivion, Inc. (AORT)

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Videos

No Data

Press releases

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Videos

No Data

Press releases

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Search stocks

Artivion, Inc. (AORT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Artivion, Inc. (AORT)

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Videos

No Data

Press releases

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.

Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript

Artivion Q1 Earnings Call Highlights

Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates

Videos

No Data

Press releases

Artivion to Participate in the 2026 Truist Securities MedTech Conference

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion Completes Acquisition of Endospan Ltd.

Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.